Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Mitsubishi Tanabe’s 9 Month Sales Rise Fueled by Strong Growth in Stelara
February 4, 2022
- Takeda Delivers Growth in All Focus Therapeutic Areas in April-December
February 4, 2022
- Novartis Japan Developing Iptacopan as Priority Product, Initially Targeting 3 Indications
February 4, 2022
- Chugai’s Sales and Profit Rose for 5 Years Running, 1 Trillion Yen-Plus Expected in 2022
February 4, 2022
- Eisai’s April-December Sales Zoom 13.4% on Lenvima Growth Overseas
February 4, 2022
- Takeda’s Osaka Plant Digitized with Cutting Edge Techs to Create Supply System for Its 1st Cell Therapy
February 4, 2022
- 650 Astellas Staffers Choose Voluntary Redundancy, Sales Force Down to 1,200
February 3, 2022
- Astellas Sees Surge in 9-Month Revenue on Xtandi Growth, US Market Recovery
February 3, 2022
- Cariprazine Adds Bipolar Indication in Singapore: Mitsubishi Tanabe
February 3, 2022
- Boehringer to Rejig Japan Sales Offices as Work Style Shifts, No Rep Cut Planned
February 2, 2022
- Sumitomo Dainippon Expects to Get Back on Growth Track in FY2025 after Latuda’s LOE: President
February 2, 2022
- Tau Antibody Licensed to US Merck Enters Clinic: Teijin
February 2, 2022
- Sumitomo Dainippon’s 9-Month Profit Sinks 33.5% on US Promotions, Other Factors
February 1, 2022
- Lenvima/Keytruda Combo Approved in Taiwan for Advanced RCC
February 1, 2022
- Buoyant Opdivo and Forxiga Drive Ono’s Growth in April-December
February 1, 2022
- Daiichi Sankyo Initiates COVID-19 Booster Study in Japan
February 1, 2022
- Kyowa Kirin Files Ophthalmic Mitomycin C Agent in Japan
February 1, 2022
- Oncolys’ Nucleocapsid Inhibitor Effective against Omicron, PI Launch by Year-End
February 1, 2022
- Shionogi’s April-Dec. Operating Profit Tumbles 40%-Plus on Antibiotic Promotion, COVID R&D
February 1, 2022
- Daiichi Sankyo’s Revenue Rises 9.8% in April-December on Upbeat Mainstays
February 1, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…